Objective: We aimed to understand the molecular pathways affected by bortezomib and arsenic trioxide treatment on myelomonocytoid cell line P39. Materials and Methods: Oligonucleotide microarray platforms were used for gene expression and pathway analysis. Confirmation studies were performed using quantitative real time PCR. Results: Bortezomib treatment has shown upregulated DIABLO and NF-κBIB (a NF-κB inhibitor) and downregulated NF-κB1, NF-κB2, and BIRC1 gene expressions. Combination treatment of the two compounds showed gene expression deregulations in concordance by the results of single bortezomib treatment. Especially, P53 was a pathway more significantly modified and a gene network centralized around the beta estradiol gene. Be...
Background: Multiple myeloma (MM), a malignancy of plasma cells, is the second most prevalent hemato...
Ajai Chari1, Amitabha Mazumder2, Sundar Jagannath11Mount Sinai School of Medicine, New York, NY, USA...
AbstractThe development of the proteasome inhibitor bortezomib is a prime example of successful benc...
Objective: We aimed to understand the molecular pathways affected by bortezomib and arsenic trioxide...
Objective: We aimed to understand the molecular pathways affected by bortezomib and arsenic trioxide...
Aim: Clinical success of the proteasome inhibitor bortezomib for multiple myeloma (MM) treatment hig...
International audienceMarrow cells from patients with higher-risk myelodysplastic syndrome (MDS) exh...
The proteasome inhibitor bortezomib has shown impressive clinical activity alone and in combination ...
Both arsenic trioxide (ATO) and bortezomib show separate antileukemic activity. With the purpose of ...
The myelodysplastic syndromes (MDS) comprise a heterogeneous group of malignant neoplasms with disti...
The objective of this study was to determine the changes in protein profiles of U-266 multiple myelo...
Background Myelodysplastic syndromes (MDS) are clonal marrow stem-cell disorders with a high risk of...
Bortezomib (Velcade) is used widely for the treatment of various human cancers; however, its mechani...
Background: Multiple myeloma (MM) is a disease of plasma cells that has fatal consequences. New agen...
Side population (SP) cells in cancers, including multiple myeloma, exhibit tumor-initiating characte...
Background: Multiple myeloma (MM), a malignancy of plasma cells, is the second most prevalent hemato...
Ajai Chari1, Amitabha Mazumder2, Sundar Jagannath11Mount Sinai School of Medicine, New York, NY, USA...
AbstractThe development of the proteasome inhibitor bortezomib is a prime example of successful benc...
Objective: We aimed to understand the molecular pathways affected by bortezomib and arsenic trioxide...
Objective: We aimed to understand the molecular pathways affected by bortezomib and arsenic trioxide...
Aim: Clinical success of the proteasome inhibitor bortezomib for multiple myeloma (MM) treatment hig...
International audienceMarrow cells from patients with higher-risk myelodysplastic syndrome (MDS) exh...
The proteasome inhibitor bortezomib has shown impressive clinical activity alone and in combination ...
Both arsenic trioxide (ATO) and bortezomib show separate antileukemic activity. With the purpose of ...
The myelodysplastic syndromes (MDS) comprise a heterogeneous group of malignant neoplasms with disti...
The objective of this study was to determine the changes in protein profiles of U-266 multiple myelo...
Background Myelodysplastic syndromes (MDS) are clonal marrow stem-cell disorders with a high risk of...
Bortezomib (Velcade) is used widely for the treatment of various human cancers; however, its mechani...
Background: Multiple myeloma (MM) is a disease of plasma cells that has fatal consequences. New agen...
Side population (SP) cells in cancers, including multiple myeloma, exhibit tumor-initiating characte...
Background: Multiple myeloma (MM), a malignancy of plasma cells, is the second most prevalent hemato...
Ajai Chari1, Amitabha Mazumder2, Sundar Jagannath11Mount Sinai School of Medicine, New York, NY, USA...
AbstractThe development of the proteasome inhibitor bortezomib is a prime example of successful benc...